T# z) i' ?0 {% H# Q4 ^
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:9 A( Y" K8 I. `. y, J
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. 4 p0 [# \! E, X0 A, Z. ?2 e |http://www.ncbi.nlm.nih.gov/pubmed/22968184 + n# D; P% |, N! m4 i$ C 1 j9 {/ A" o A( ?2 X0 z+ k依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制5 p9 l& a. X9 q7 r# M/ y* t http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx